Insider filing
Traded Oct 8 · filed the same day
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Sep 11, 2026 · Filed Sep 11, 2026
Edwards Lifesciences's CVP, TAVR sold $54K of Edwards Lifesciences shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$54,169
Shares × reported transaction price
50 days after results of Jul 23, 2026, 54 days before results of Nov 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $84.37 on Sep 11, 2026, 16% above its 52-week low and 11% below its high, after a 3% drop over the previous 30 trading days
52-week range $72.65 (Oct 16, 2025) to $95.18 (Jul 6, 2026), 52% of the way up, from 251 adjusted closes. 30 trading days earlier: $86.92 on Jul 30, 2026. Describes the past only, not a forecast
RSI 31, at its 200-day average, 5% under its 50-day average, 11% below the 52-week high, 20-day volatility 21% a year, against the S&P 500: −8 points over 1 month, −5 points over 3 months, −15 points over 6 months
From the adjusted closes up to Sep 11, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.
Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant
FDA approved Autus Size-Adjustable Valve on Oct 1, 2026, 20 days after this trade.
Premarket approval (PMA): Heart-valve, polymeric. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.3% | +1.7% | +1.6% |
| 30 days | +1.1% | +1.1% | −0.1% |
Past results only. Not a forecast.
Insider filing
Traded Oct 8 · filed the same day
Derivative exercise or conversion — not an open-market buy.
Daniel J. Lippis (CVP, TAVR) sold ~$53K of Edwards Lifesciences
Planned saleInsider filing
Traded Oct 8 · filed the same day
Derivative exercise or conversion — not an open-market buy.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.